Closed
The EARLY Trial was looking to determine the Efficacy and safety of atabecestat in participants who are Asymptomatic at Risk for developing Alzheimer’s dementia. The study sponsor, Janssen, sought to use the latest advances to assess a participant’s risk associated with beta-amyloid and memory loss, and test whether a treatment that reduces amyloid formation would slow memory loss associated with Alzheimer’s disease (AD).